Viralytics Limited
(ASX:VLA) says it’s reached a milestone in the clinical trial of a drug for late stage melanoma patients.
The biotechnology company’s lead study investigator Dr Robert Andtbacka told the American Society of Clinical Oncology that 35 patients had been enrolled in the clinical trial, with a target of 54.
Dr Andtbacka says patients injected with the drug have not experienced any adverse events.
He says he has been encouraged by the early results and that the enrolment of the 35th patient marked the end of stage one of the trial.
Viralytics says it expects strong progress on the study during the second half of 2013.
Viralytics posted a net loss of $2.5 million in the first half of the current financial year.
